Abstract:Rationale and Objectives: The classification of patients based on pathology and molecular features is important for improving WHO grade II glioma patient prognosis, especially for the initially diagnosed patients. Less invasive and more convenient methods for the prediction of the pathological type and gene status are desired. Materials and Methods: This study investigates the ability to use conventional magnetic resonance imaging (MRI) and computed tomography (CT) features for determining the Isocitrate Dehydrogenase (IDH)-mutant and 1p/19q-codeletion status, through a retrospective review of information obtained from 189 WHO grade II glioma patients. Diffuse astrocytoma (IDH-mutant), Diffuse astrocytoma (IDH- wildtype) and Oligodendroglioma (IDH-mutant and 1p/19q co-deletion) were included in this cohort. All patients were divided into IDH-mutant group and IDH-wildtype group according to the IDH R132H mutation status. Moreover, all patients were divided into 1p/19q co-deletion group and 1p/19q non-codeletion group according to the 1p and 19q chromosome status. Patients underwent pre-operative CT and MRI scans, followed by operation and histopathological analyses, including immunohistochemistry and polymerase chain reaction analysis for IDH mutants, and fluorescence capillary electrophoresis analysis for the 1p/19q co-deletion. The x2 test, logistical regression and receiver operating characteristic curve analysis were conducted for statistical analysis. Results: IDH-mutant group patients exhibited a higher calcification frequency (25.2% vs 2.4%, p = 0.006) and lower frequency of T1 enhancement (20.4% vs 38.1%, p = 0.028) comparing patients in IDH-wildtype group, while 1p/19q co-deletion group patients exhibited a higher calcification frequency (46.67% vs 2.6%, p < 0.001) and lower homogenous signal frequency in T2WI (12.0% vs 31.6%, p = 0.014), sharp lesion margins (14.7% vs 43.0%, p = 0.010), T2/fluid attenuated inversion recovery mismatch signs (22.7% vs 50.9%, p = 0.001), and subventricular zone involvement (64.0% vs 15.8%, p = 0.021) comparing patients in 1p/19q non-codeletion group. According to the results of receiver operating characteristic analysis, these features were observed to have certain diagnostic abilities, especially with regard to combination parameters, which had a high diagnostic capability, with an area under the curve of 0.848. Conclusion: Conventional MRI and CT features, which still represent the most convenient and widely used predictive method, might be a promising noninvasive predictor for differentiating between varied WHO grade II gliomas. Patients with calcification and T1 nonenhancement are more likely to be IDH-mutant. Moreover, patients with noncalcification, homogenous signal, sharp lesion margins, subventricular zone involvement on T2 and T2/fluid attenuated inversion recovery mismatch signs are more likely to be 1p/19q non-codeletion.

Oncometabolite 2-HG in glioma evolution and recent progress of detection method

Detection of "oncometabolite" 2-Hydroxyglutarate by Magnetic Resonance Analysis As A Biomarker of Idh1/2 Mutations in Glioma

Rapid Diagnosis of IDH1-mutated Gliomas by 2-HG Detection with Gas Chromatography Mass Spectrometry.

P08.65 the Mechanisms of Oncometabolites in Epigenetic Control, DNA Repair, Neural Development and Gliomagenesis

Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma

Deciphering the Multifaceted Roles and Clinical Implications of 2-Hydroxy-glutarate in Cancer

A genetically encoded fluorescent sensor enables sensitive and specific detection of IDH mutant associated oncometabolite D-2-hydroxyglutarate

Deciphering the multifaceted roles and clinical implications of 2-hydroxyglutarate in cancer

Absolute quantification of 2-hydroxyglutarate on tissue by matrix-assisted laser desorption/ionization mass spectrometry imaging for rapid and precise identification of isocitrate dehydrogenase mutations in human glioma

The diagnostic efficiency of integration of 2HG MRS and IVIM versus individual parameters for predicting IDH mutation status in gliomas in clinical scenarios: A retrospective study

Tmic-53. Use Of Cerebral Open-Flow Microperfusion To Identify Potential Oncometabolite, L-2-Hydroxyglutarate, In Glioblastoma Chemotherapy Adaptation

MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma

Progress in the Application of Molecular Biomarkers in Gliomas

Magnetic resonance spectroscopy of isocitrate dehydrogenase mutated gliomas: current knowledge on the neurochemical profile

Idh1/Idh2 Mutations Define The Prognosis And Molecular Profiles Of Patients With Gliomas: A Meta-Analysis

Mitochondrial Serine Hydroxymethyltransferase 2 is a Potential Diagnostic and Prognostic Biomarker for Human Glioma.

To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma

Selective Detection of the D-Enantiomer of 2-Hydroxyglutarate in the Csf of Glioma Patients with Mutated Isocitrate Dehydrogenase

2-Hydroxyglutarate as an MR spectroscopic predictor of an IDH mutation in gliomas2-Hydroxyglutarat als MR-spektroskopisch erfassbarer Prädiktor einer IDH-Mutation bei Gliomen

Clinical prognostic value of isocitrate dehydrogenase mutation, O-6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in glioma patients

The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas.